What is it?
Synthetic 28-amino-acid immunomodulatory peptide
Peptide Library · checked July 17, 2026
Thymosin Alpha-1
Thymosin alpha-1 has human research. “Immune support” is still too vague to describe it: the trials span different illnesses, populations, and outcomes, and a large phase 3 sepsis trial found no mortality benefit. It is not FDA approved in the United States.
TL;DR
The lowdown
Four answers first. The source record follows.
What do humans show?
Trials exist in infections, cancer, sepsis, and other conditions; results are mixed and indication-specific
Where does FDA stand?
Not FDA-approved in the United States; advisory committee voted against 503A list inclusion
What is known—and not?
FDA noted that clinical studies often described thymosin alpha-1 as well tolerated, but also found the safety information inadequate for the proposed compounded products and uses. Peptide aggregation, impurities, immunogenicity, formulation, route, and patient population all affect risk.
U.S. status · July 17, 2026
Approval, compounding, product, sport.
- FDA approval
- Not FDA-approved; PCAC voted against 503A Bulks List inclusion in 2024
- U.S. federal record
- Not FDA-approved; PCAC voted against 503A Bulks List inclusion in 2024
- Product identity
- No separate finished-product identity conclusion is recorded in this reviewed source.
- Sport
- No WADA status recorded in the reviewed source.
This reports the dated federal and sport record. It does not determine whether a particular product or transaction complies with state or federal law, and it is not legal advice.
01
What it is
Thymosin alpha-1 is a synthetic version of a 28-amino-acid peptide originally isolated from thymus tissue. It has been studied as an immunomodulator in multiple serious conditions and is licensed in some countries.
That history makes it different from a peptide supported only by cell or animal experiments. It still does not create a general U.S. approval or prove a nonspecific “immune boost.”
02
What humans actually show
- Large phase 3 sepsis trial: The TESTS trial randomized 1,106 adults with sepsis across 22 centers in China. Twenty-eight-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo; the difference was not statistically significant.
- Earlier literature: Smaller and methodologically weaker studies had suggested benefit in sepsis. The larger blinded trial is important because it did not confirm a mortality benefit.
- Condition-by-condition problem: Evidence in sepsis cannot establish effectiveness for chronic fatigue, cancer, viral illness, vaccination response, or routine wellness. Each use requires its own trial evidence and risk assessment.
- Compounded-product gap: FDA reported that its literature search did not identify human studies that specifically used compounded thymosin alpha-1 products.
03
FDA and U.S. status
Thymosin alpha-1 is not an FDA-approved drug in the United States. In December 2024, the Pharmacy Compounding Advisory Committee voted 17 to 4 against adding both the free base and acetate forms to the 503A Bulks List.
FDA's briefing concluded that the evaluated evidence did not support effectiveness for the reviewed uses and raised characterization, immunogenicity, and safety-information concerns. The advisory vote and drug approval are separate regulatory processes.
04
Risks and warning limits
FDA noted that clinical studies often described thymosin alpha-1 as well tolerated, but also found the safety information inadequate for the proposed compounded products and uses. Peptide aggregation, impurities, immunogenicity, formulation, route, and patient population all affect risk.
“Immune modulating” is not automatically the same as harmless. People with cancer, transplants, autoimmune disease, infection, or multiple medications need individualized medical assessment.
05
What would change this answer
- Any final FDA action following the 2024 advisory vote
- Replication or follow-up of the TESTS trial
- Better indication-specific randomized trials
- Claims that move from treatment research in seriously ill patients to routine wellness use
06
Sources and records
- FDA briefing document for thymosin alpha-1-related substances, 2024
- FDA Pharmacy Compounding Advisory Committee final minutes, 2024
- Wu et al., 2025 — 1,106-person phase 3 sepsis trial
Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.
What changed
Added the source-verified Claim Check to the structured claim/source/change registry.
What would change our answer
A well-controlled human study tied to the exact product, population, route, and claimed outcome could change the answer. Mechanism, anecdotes, or a different product cannot substitute for that evidence.
Version history · 1 entry
- v1 · 2026-07-17Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: PepCurrent explains public evidence and regulatory records. We do not evaluate individual products, recommend use, name vendors, or provide protocols.